|
Post by mnholdem on Jan 17, 2018 7:33:36 GMT -5
GlaxoSmithKline Rumored to be Mulling $1.65B Bid for Partner Vectura Jan 16, 2018
There are rumors that GlaxoSmithKline might make a $1.65 billion bid for UK-based Vectura. That seems like a very specific bit of speculation.
The Telegraph first reported the rumors, citing a possible bid of more than 175 per share, which would be a total bid of around 1.2 billion pounds, or $1.65 billion U.S.
Vectura focuses on devices and formulations for inhaled respiratory medications. Andrew McConaghie, writing for PharmaPhorum, notes, “The biotech firm’s share price fell nearly 40 percent over the course of 2017, largely because the FDA had rejected Vectura and Hikma’s generic version of Advair, but the companies now hope to resolve these problems in Q1 this year.”
GSK is partnered with Vectura already. GSK uses Vectura’s smart inhaler technology in its next-generation Ellipta respiratory products. But McConaghie points out that, although buying Vectura would bolster its respiratory franchise, Vectura has a lot of partnerships with GKS’s competitors. Vectura’s collaborations include Mundipharma, Bayer, and Novartis. They have also all been cited as potential buyers of Vectura.
McConaghie writes, “Its financial problems led Vectura’s chief executive James Ward-Lilley to announce a new business strategy in early January. He unveiled a shift in its focus towards lower risk development opportunities in high potential generics molecules in its pipeline. It will also end new investment in higher risk, novel molecules in early stage programs, and says it will look at opportunities to partner existing programs.”
And if there is an actual bid being planned, that would be a change for GSK as well. Under previous chief executive officer Sir Andrew Witty, the company conducted very little M&A activity. But the new chief executive officer Emma Walmsley is likely taking a different approach.
---
I post this as a reminder that there are big markets for inhalable generics. - MnHoldem
|
|
|
Post by akemp3000 on Jan 17, 2018 7:58:01 GMT -5
Nice to see a strong speculative play in the inhalation arena. It would take a whole lot more than $1.65B for a BP to acquire MNKD. Just saying...
|
|
|
Post by kite on Jan 17, 2018 8:05:01 GMT -5
Nice to see a strong speculative play in the inhalation arena. It would take a whole lot more than $1.65B for a BP to acquire MNKD. Just saying... Do you think thats why no deal has happened yet? That maybe the deals that have been offered were too low? I think so!
|
|
|
Post by akemp3000 on Jan 17, 2018 8:19:54 GMT -5
I agree. IMO...Mannkind's not for sale, at least not yet. Mike has to first build the value that Al Mann envisioned. IF there have been any discussions regarding offers, they would more likely be associated with acquiring a minority portion of the company for funds that would jump start a collaboration, increase global marketing for Afrezza and begin building the pipeline. A sale might then follow somewhere down that path.
|
|
|
Post by mnholdem on Jan 17, 2018 8:25:34 GMT -5
It's also a fair analysis, I think, that with the nation's current focus on exorbitant drug prices (Afrezza included) that FDA-approved Technosphere would marry up nicely with FDA-approved generics for multiple indications.
MannKind totally screwed up by not taking advantage of the Mylan furor over their EpiPen epinephrine scandal. They also missed the opportunity to announce a major price reduction for Afrezza when they got it back from Sanofi, which would have had a MAJOR marketing impact.
The current CEO achieved virtually zero results as Commercial Officer other than stopping the exodus away from Afrezza by doctors. I don't see him out promoting Afrezza on the medical circuit other than at conferences where it's obvious he's drumming up $$$ investments. When he took over as CEO, there was an immediate reshuffling of the pipeline and then...nothing. MannKind doesn't even have a Chief Medical Officer anymore.
So I sincerely hope that MannKind on track with their plan that Mike presented last year and that an IND for Trepostinil is going to be filed with the FDA and announced by the end of February. Are the international marketing applications for Afrezza being done according to the plan, which were supposed to be in submitted in countries that would account for more than 50% of the world's diabetic population? In a recent interview (was it with Motley Fool) Mike said MannKind was planning on submitting ALL those international applications within 12 months.
There is a reason that Wall Street isn't flocking to MannKind. CEO Michael Castagna is NOT experienced in disruptive marketing and I doubt he's contracted any firm that is. Instead, he appears to be playing by the pharmaceutical industry's playbook. I had higher expectations for him, but he's not impressing me (or Wall Street) with anything other than his ability to sell an idea or two.
Rant over. Good fortune all.
|
|
|
Post by kbrion77 on Jan 17, 2018 8:35:10 GMT -5
Nice to see a strong speculative play in the inhalation arena. It would take a whole lot more than $1.65B for a BP to acquire MNKD. Just saying... Almost $14 a share buyout sorry but I'm taking it. That's a 54% gain for me. BP could have made a move when this company was valued at $80MM, there is a reason they didn't. A $50-$75MM investment in MNKD would go a long way from anyone yet BP/investors would rather allocate that money to ideas or companies that haven't even made it through phase 1 trials, and we have a fully approved drug, they simply don't believe in it.
|
|
|
Post by digger on Jan 17, 2018 11:21:16 GMT -5
|
|
|
Post by dreamboatcruise on Jan 17, 2018 13:14:36 GMT -5
Nice to see a strong speculative play in the inhalation arena. It would take a whole lot more than $1.65B for a BP to acquire MNKD. Just saying... That seems to be in the same category as me thinking I'd turn down a date with certain fashion models because I don't think they'd be good conversation.
|
|
|
Post by kc on Jan 17, 2018 13:26:26 GMT -5
GlaxoSmithKline Rumored to be Mulling $1.65B Bid for Partner Vectura Jan 16, 2018
There are rumors that GlaxoSmithKline might make a $1.65 billion bid for UK-based Vectura. That seems like a very specific bit of speculation.
The Telegraph first reported the rumors, citing a possible bid of more than 175 per share, which would be a total bid of around 1.2 billion pounds, or $1.65 billion U.S.
Vectura focuses on devices and formulations for inhaled respiratory medications. Andrew McConaghie, writing for PharmaPhorum, notes, “The biotech firm’s share price fell nearly 40 percent over the course of 2017, largely because the FDA had rejected Vectura and Hikma’s generic version of Advair, but the companies now hope to resolve these problems in Q1 this year.”
GSK is partnered with Vectura already. GSK uses Vectura’s smart inhaler technology in its next-generation Ellipta respiratory products. But McConaghie points out that, although buying Vectura would bolster its respiratory franchise, Vectura has a lot of partnerships with GKS’s competitors. Vectura’s collaborations include Mundipharma, Bayer, and Novartis. They have also all been cited as potential buyers of Vectura.
McConaghie writes, “Its financial problems led Vectura’s chief executive James Ward-Lilley to announce a new business strategy in early January. He unveiled a shift in its focus towards lower risk development opportunities in high potential generics molecules in its pipeline. It will also end new investment in higher risk, novel molecules in early stage programs, and says it will look at opportunities to partner existing programs.”
And if there is an actual bid being planned, that would be a change for GSK as well. Under previous chief executive officer Sir Andrew Witty, the company conducted very little M&A activity. But the new chief executive officer Emma Walmsley is likely taking a different approach.
---
I post this as a reminder that there are big markets for inhalable generics. - MnHoldem Makes one wonder why Amphastar does not make some move for Techno or an interest in MannKind?
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company that is engaged in the development, manufacture and marketing of generic and proprietary injectable and inhalation products.
|
|
|
Post by dreamboatcruise on Jan 17, 2018 13:38:36 GMT -5
It's also a fair analysis, I think, that with the nation's current focus on exorbitant drug prices (Afrezza included) that FDA-approved Technosphere would marry up nicely with FDA-approved generics for multiple indications.
MannKind totally screwed up by not taking advantage of the Mylan furor over their EpiPen epinephrine scandal. They also missed the opportunity to announce a major price reduction for Afrezza when they got it back from Sanofi, which would have had a MAJOR marketing impact.
The current CEO achieved virtually zero results as Commercial Officer other than stopping the exodus away from Afrezza by doctors. I don't see him out promoting Afrezza on the medical circuit other than at conferences where it's obvious he's drumming up $$$ investments. When he took over as CEO, there was an immediate reshuffling of the pipeline and then...nothing. MannKind doesn't even have a Chief Medical Officer anymore.
So I sincerely hope that MannKind on track with their plan that Mike presented last year and that an IND for Trepostinil is going to be filed with the FDA and announced by the end of February. Are the international marketing applications for Afrezza being done according to the plan, which were supposed to be in submitted in countries that would account for more than 50% of the world's diabetic population? In a recent interview (was it with Motley Fool) Mike said MannKind was planning on submitting ALL those international applications within 12 months.
There is a reason that Wall Street isn't flocking to MannKind. CEO Michael Castagna is NOT experienced in disruptive marketing and I doubt he's contracted any firm that is. Instead, he appears to be playing by the pharmaceutical industry's playbook. I had higher expectations for him, but he's not impressing me (or Wall Street) with anything other than his ability to sell an idea or two.
Rant over. Good fortune all.
But the whole point of marrying technosphere with an older fallen/falling off of patent API is that the resulting product would not be a generic. It would likely have its own patents extending out some time and command a branded premium.
|
|
|
Post by akemp3000 on Jan 17, 2018 14:55:31 GMT -5
Nice to see a strong speculative play in the inhalation arena. It would take a whole lot more than $1.65B for a BP to acquire MNKD. Just saying... Almost $14 a share buyout sorry but I'm taking it. That's a 54% gain for me. BP could have made a move when this company was valued at $80MM, there is a reason they didn't. A $50-$75MM investment in MNKD would go a long way from anyone yet BP/investors would rather allocate that money to ideas or companies that haven't even made it through phase 1 trials, and we have a fully approved drug, they simply don't believe in it. Mannkind management isn't about to sell the company at a loss to help retail investors. TS science works beautifully and the people that count believe in it, i.e. diabetics using Afrezza, Mannkind management and Greenhill who continues to help the company maneuver the current phase. Oh...plus all the retail longs who won't give up a share regardless of continuing FUD. If TS/Afrezza was a failed science, then $1.65B would be an excellent salvage price.
|
|
|
Post by boca1girl on Jan 17, 2018 15:02:30 GMT -5
GlaxoSmithKline Rumored to be Mulling $1.65B Bid for Partner Vectura Jan 16, 2018
There are rumors that GlaxoSmithKline might make a $1.65 billion bid for UK-based Vectura. That seems like a very specific bit of speculation.
The Telegraph first reported the rumors, citing a possible bid of more than 175 per share, which would be a total bid of around 1.2 billion pounds, or $1.65 billion U.S.
Vectura focuses on devices and formulations for inhaled respiratory medications. Andrew McConaghie, writing for PharmaPhorum, notes, “The biotech firm’s share price fell nearly 40 percent over the course of 2017, largely because the FDA had rejected Vectura and Hikma’s generic version of Advair, but the companies now hope to resolve these problems in Q1 this year.”
GSK is partnered with Vectura already. GSK uses Vectura’s smart inhaler technology in its next-generation Ellipta respiratory products. But McConaghie points out that, although buying Vectura would bolster its respiratory franchise, Vectura has a lot of partnerships with GKS’s competitors. Vectura’s collaborations include Mundipharma, Bayer, and Novartis. They have also all been cited as potential buyers of Vectura.
McConaghie writes, “Its financial problems led Vectura’s chief executive James Ward-Lilley to announce a new business strategy in early January. He unveiled a shift in its focus towards lower risk development opportunities in high potential generics molecules in its pipeline. It will also end new investment in higher risk, novel molecules in early stage programs, and says it will look at opportunities to partner existing programs.”
And if there is an actual bid being planned, that would be a change for GSK as well. Under previous chief executive officer Sir Andrew Witty, the company conducted very little M&A activity. But the new chief executive officer Emma Walmsley is likely taking a different approach.
---
I post this as a reminder that there are big markets for inhalable generics. - MnHoldem Makes one wonder why Amphastar does not make some move for Techno or an interest in MannKind?
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company that is engaged in the development, manufacture and marketing of generic and proprietary injectable and inhalation products.
They still have first right of refusal on distribution rights in China (? Far East?). I thought they would have moved on that opportunity by now.
|
|
|
Post by babaoriley on Jan 17, 2018 23:56:50 GMT -5
Nice to see a strong speculative play in the inhalation arena. It would take a whole lot more than $1.65B for a BP to acquire MNKD. Just saying... akemp, respectfully, you're very far off in your thinking. Right now a $6 offer would be accepted in a heartbeat. Don't fool yourself, and don't fool others. Didn't you read what MNHOLDEM had to say? $6, please!
|
|
|
Post by babaoriley on Jan 18, 2018 0:07:38 GMT -5
It's also a fair analysis, I think, that with the nation's current focus on exorbitant drug prices (Afrezza included) that FDA-approved Technosphere would marry up nicely with FDA-approved generics for multiple indications.
MannKind totally screwed up by not taking advantage of the Mylan furor over their EpiPen epinephrine scandal. They also missed the opportunity to announce a major price reduction for Afrezza when they got it back from Sanofi, which would have had a MAJOR marketing impact.
The current CEO achieved virtually zero results as Commercial Officer other than stopping the exodus away from Afrezza by doctors. I don't see him out promoting Afrezza on the medical circuit other than at conferences where it's obvious he's drumming up $$$ investments. When he took over as CEO, there was an immediate reshuffling of the pipeline and then...nothing. MannKind doesn't even have a Chief Medical Officer anymore.
So I sincerely hope that MannKind on track with their plan that Mike presented last year and that an IND for Trepostinil is going to be filed with the FDA and announced by the end of February. Are the international marketing applications for Afrezza being done according to the plan, which were supposed to be in submitted in countries that would account for more than 50% of the world's diabetic population? In a recent interview (was it with Motley Fool) Mike said MannKind was planning on submitting ALL those international applications within 12 months.
There is a reason that Wall Street isn't flocking to MannKind. CEO Michael Castagna is NOT experienced in disruptive marketing and I doubt he's contracted any firm that is. Instead, he appears to be playing by the pharmaceutical industry's playbook. I had higher expectations for him, but he's not impressing me (or Wall Street) with anything other than his ability to sell an idea or two.
Rant over. Good fortune all.
Drumming up dollars is a really important thing to MNKD, unfortunately. I sure liked the beat of that drummer when raising cash at $6 per share! I've been pretty busy with my unfortunate day job, and I missed this nugget of a post until now - although Sports was certainly all a-twitter over it! So, to read your post, Mike sounds a little like our very own Anti-Christ. I'm on board with that, but an Anti-Christ is sometimes what you need to battle in these parts. I hope that your post had therapeutic value. I have resigned myself to the happenings of this Friday, it's been sitting there like a huge boulder in the roadway for far too long, and we're within a few feet of it now. I'm hoping all in a similar boat can get over it, and look forward with a sense that we just might make it. I still long for a buyout, double whatever our share price is at any point in time, so long as our share price is not under $2.
|
|
|
Post by akemp3000 on Jan 18, 2018 5:32:57 GMT -5
Nice to see a strong speculative play in the inhalation arena. It would take a whole lot more than $1.65B for a BP to acquire MNKD. Just saying... akemp, respectfully, you're very far off in your thinking. Right now a $6 offer would be accepted in a heartbeat. Don't fool yourself, and don't fool others. Didn't you read what MNHOLDEM had to say? $6, please! So...Kent Kresa, the Chairman of the Board of Mannkind, recently invests a cool million at $6 and someone?? anyone?? actually believes the company would now sell for this price. As MC says, Priceless!
|
|